German legislation demands controlling measures for outpatient drug costs. As of 2017 the health insurance actors rose to a challenge to reform the benchmark system on the federal state level. We look at the previous system applied until 2015, the improvements in 2016 and the method the regional parties agree on for 2017. After discussing hard-and software systems and the underlying data briefly we describe the flaws of the old approach and develop a general model for controlling measures in the outpatient field. Finally we present the first real world applications of the new model: a patient type classification system leading to target costs and a derived distance structure of physicians regarding their prescription behaviour.
INTRODUCTION
In Europe and especially in Germany rising pharmaceutical expenditures put the health service at risk. Every modern health care system has to ensure the quality and equity of care while keeping the cost down. Therefore controlling measures were established by the German legislation as early as in 1993. Since 1995 this is subject to regional negotiations between Statutory Health Insurances (SHI) and SHI associated physicians. This type of regulation aims to limit expenditures per patient without restricting the necessary treatment.
Of the exiting two types of instruments, the first one puts German patients/cases in certain more or less morbidity related cost groups, the other promotes or restricts drug classes with different economic characteristics but same curative effects. We will look at those using health insurance data of the German Federal State Schleswig-Holstein in 2015.
In the years from 1995 till 2015 physician groups got three different treatment case budgets for each insurance status defined by statutory health insurance (member [M] , dependent coverage [D] and retired [R] ). Some regions merged status [M] and [D] . Several expensive drug substances and pharmaceuticals regulated by treatment regimen are excluded resulting in internal inconsistencies and uncertainties regarding all participating players.
Budgets are calculated using expenditure shares for the mentioned case groups per physician group in a reference period (last year) and the negotiated target volume of expenditure for the resent year.
In December 2013 the social welfare court of Dresden passed the sentence that guide values/budgets have to be based on age groups. Additionally the Federal Social Court judged that authorities have an obligation to regulate atypical drug prescriptions. As an immediate consequence regarding the budget calculation for 2016 four age groups superseded insurance status: 0-15, 16-49, 50-64 and 65 and above. Those groups, utilized in all statutory health insurances, have a very poor age resolution for this field of application in general.
From 2017 on, the federal legislator made regional negotiated far-reaching reforms of controlling measures possible (Versorgungsstärkungsgesetz = Supply Support Act). A new system developed in this context is expenditure controlling by Morbidity Related Groups (MRG). MRG is an adaption of the Diagnosis-Related-Group-System (DRG) used for classification and compensation of hospital cases and put into effect in 2003 by German legislation. It is based on similar systems elsewhere: Since the first use for hospital payment in the United States in the early 1980s, DRG-type systems have become the main method of hospital payment in the majority of OECD countries. The German version (G-DRG) is based on the Australian DRG-system (AR-DRG).
Hereinafter we will compare the systems based on insurance status, age groups and MRG, including some new results for MRG. The previous model used till 2016 applies prescription data, treatment cases and status defined by statutory health insurance/age groups. The implementation is straight forward. Treatment cases in a certain age/status group get their share of the negotiated volume of expenditure based on the development of last years'expenditures and treatment cases.
MATERIAL AND METHODS
The new MRG-model requires prescription data, the ATC classification and physician group information depending on the model configuration. It can be defined as follows: B = set of physicians/practices F = set of physician groups There is a transformation mapping physicians/practices to groups: f = f (b) while splitting up practices containing different physician groups.
is the mapping of patients and physicians whereas the transformation D = D(p) maps patients p ∈ P(b) to the prescribed drugs. Multiple prescriptions of one drug are counted repeatedly. o(d) is a quantity factor for d ∈ D representing the ration of package size of the prescription drug in relation to the biggest one available. A pharmaceutical classification system (e.g. ATC4) as transformation: a = a(p), a ∈ A used identification of similar medicinal products. The drugs d ∈ D are linked to costs by the cost function:
The age of the patient is defined by:
ATC with the highest costs = basic MRG is characterized byk(p, c) ≥k(p, a) for all a ∈ A. In case of the occurrence of several c i the lexicographically dominating element is chosen. c = c(p) is the transformation to determine patients basic MRG. Number of ATC4 groups per patient (multimedication) is defined as:
The number of prescriptions for patient p ∈ P assigned to basic MRG c(p) is represented by:
We define threshold values for subgroups:
(v 0 , · · · , v 9 ) = (0.5, 0.75, 1.25, 1.5, 2.0, 2.5, 5, 10)
shall be the mean of x ∈ X. The costs of basic MRG c ∈ A in the physician group are defined as:
and adding the age dimension the term changes to:
whereby the age related severity is given by:
Costs differentiated by multimorbidity are expressed by the formula:
with the corresponding degree of severity:
The same can be done by looking at prescription intensity:
Total degree of severity is given by:
The MRG including severity levels is recalculated with respect to physician groups:
Thereby we get the target cost for benchmarking the physician:
In our setting we look for the group with the highest drug costs within a quarter for each consulted physician for a certain patient. This group should strongly be related to the morbidity of the patient and we will call it therefore Morbidity Related Group (MRG). One considers the costs as a proxy for the severity of drug treatment and could also take other weight functions instead of cost. The following is an example regarding a diabetes patient who belongs to the basic group A10A (Insulins and analogues) with total patient cost of 1,536.75 e: As an initial adjustment factor the age of patients can be applied. In each 5 year group of patients the ratio of costs per patient in the subgroup compared to the whole MRG was considered. If the ratio lies in certain intervals (0-0.5, 0.5-0.75, 0.75-1.25,..., 10) the age severity level 0,1,...,9 were assigned. The same can be conducted with respect to other factors correlated with morbidity. By using subgroup structures a risk adjustment can be accomplished. All of this has not to be precise on the level of the patient but on the physicians level. Regarding the considered MRG A10A (Insulins and analogues) seven degrees of severity in the range of 101.27 e up to 1,385.61 e resulted: We divide the (basic) MRG into several severity levels that will be analysed by Lorenz curves and the corresponding Gini coefficients: Additionally the Shannons entropy (− ∑ p i log(p i )) can be applied to the patient type structure in each physicians group with respect to the MRG basic groups: 
RESULTS
The application of the treatment case oriented approaches over the last decades showed that these systems are incapable of considering age and progress related increase of prescription costs. Recent analysis of the age distribution of treatment cases in each Statutory Health Insurance status group shows that the applied age groups might be too coarse and unsuited as the insurance status for the morbidity related depiction of prescription costs per patient: Hence, a new system based on MRG is introduced in 2017. There is little correlation between the results obtained by the previous and the new results on the practitioners level. That's due to the fact that many factors were disregarded in the past and inconsistencies were compensated by "manual intervention": Sorting the practices in ascending order for all affected groups due to their MRG benchmarking result and comparing those to the outcomes of the older system demonstrates the progress in model adaption made: In those new MRG models all patients of a certain practice are classified and a specific structure for each practice is the result. As an example, we consider a physician with 14.0 % of his patients in the MRG A10A (Insulins and analogues) and 11.8 % patients in the MRG V04C (other diagnostic agents = test strips measuring glucose). In this group of general practitioners (GP) patients in those groups only account for 3.8 % in these two groups. The physician can thereby be identified as a diabetologist: Regarding orthopedics we observe a patient type structure, in which 42.9 % of all patients belong to the MRG M01A (antiinflammatory and antirheumatic products, non-steroids). The 10 leading positions cover 94.6 % of the costs. Costs again depend mainly on the medical discipline. In oncology average costs per patient are 15,288.17 e in the MRG L04A (immunosuppressive agents including all the other drugs for the patient) versus 2,515.02 e for orthopedics. In urology the top ten positions with respect to the number of patients cover 83.6 % of the costs. In the case of GP these costs are only 44.2 %: The MRG patient shares can be utilized to generate distance measures for the clustering of all practices/physicians. Let p k m be the fraction of patients with MRG m (m ∈ M) for the physician k (k ∈ P). With respect to the medical discipline s (s ∈ S) and let q s m be the respective fraction. Let r and s be such fractions for physicians or medical disciplines we can use a Manhattan distance: The spherical distances are differentiable with respect to the components of r and s and thereby is more suitable for optimization procedures.
Comparison of Different Implementations of a Process Limiting Pharmaceutical Expenditures Required by German Law
We can define the discipline t ∈ S of a physician k ∈ P by the value s ∈ S for which:
has a minimal value. The distance of a physician to a group measures to which extent he is typical or not. Extreme values may be a hint for the need for special considerations. One can use cluster methods in order to receive a classification of physicians without the use of their medical discipline which is primarily determined by admission law.
CONCLUSIONS
The 2016 switch from health insurance status to age groups did not eliminate the flaws of the old benchmarking/budget approach. New promising ideas on the regional level like MRG have a huge potential still to be researched and utilized. The necessary data is provided, hard-/software and knowledge are available. Steady change and especially new form of health care require adapting benchmarking systems on a sound data and legal foundation. Therefore MRG seems to be a highly suitable approach meeting the criteria.
